Trends of cutaneous squamous cell carcinoma in the Netherlands: Increased incidence rates, but stable relative survival and mortality 1989–2008  by Hollestein, L.M. et al.
European Journal of Cancer (2012) 48, 2046–2053Ava i l ab l e a t www.s c i enced i r ec t . com
journa l homepage : www.e jcon l ine . comTrends of cutaneous squamous cell carcinoma
in the Netherlands: Increased incidence rates, but stable
relative survival and mortality 1989–2008L.M. Hollestein a,⇑, E. de Vries a,b,c, T. Nijsten aaDepartment of Dermatology, Erasmus Medical Center, Rotterdam, The Netherlands
bDepartment of Public Health, Erasmus Medical Center, Rotterdam, The Netherlands
cEindhoven Cancer Registry, Eindhoven, The Netherlands
Available online 16 February 201209
do
⇑
10KEYWORDS
Cutaneous squamous cell
carcinoma
Epidemiology
Incidence
Mortality
Population-based
Survival59-8049 2012 Elsevier Ltd
i:10.1016/j.ejca.2012.01.003
Corresponding author: Addr
70 35 886; fax: +31 10 70 3
E-mail address: l.hollestein@.
ess: Dep
3 822.
erasmus
Open accAbstract Background: Incidence rates of cutaneous squamous cell carcinoma (SCC) are
increasing in many countries, though detailed information is scarce.
Objectives: To describe detailed trends in incidence rates, relative survival and estimate mor-
tality rates of SCC in the Netherlands.
Methods: Information on newly diagnosed SCC patients between 1989 and 2008 was obtained
from the Netherlands Cancer Registry (NCR). Information of non-melanoma skin cancer
(NMSC) mortality was obtained from Statistics Netherlands. European Standardised Rates
(ESR) and Estimated Annual Percentage Change (EAPC) were calculated. Incidence rates
were ﬁtted to two different models and predicted by the best ﬁtted model. Cohort-based
and multivariate survival analyses were performed to assess changes over time.
Results: The ESR increased from 22.2 to 35.4 per 100,000 inhabitants for males and from 7.8
to 20.5 for females. The EAPC was 6.9% (95% conﬁdence interval: 5.8–8.7) for males and
9.2% (95% CI: 7.5–11.0) for females. Incidence rates increased for all body sites, except for
the lips, where a decreasing trend for males was observed. The predicted ESR in 2020 is
46.9 per 100,000 inhabitants for males and 28.7 for females. The 5-year relative survival rate
was 92.0% (95% CI: 91.3–92.8) for males and 94.9% (95% CI: 94.0–95.7) for females and
remained stable over time. Overall relative survival was better for females, but females with
advanced disease had a 30.4 relative excess risk of dying compared to those in stage I. This
difference was 9.9 for men. The estimated mortality rate decreased with –1.9% (95% CI:
–3.1% to –0.7%) annually.
Conclusions: Incidence rates of SCC increased rapidly. Relative survival was high, as most
SCCs were diagnosed in stage I. Nevertheless, the number of newly diagnosed patients may
exceed 11,000 by 2020, emphasising the need to improve methods to prevent skin cancer.
 2012 Elsevier Ltd.Open access under the Elsevier OA license. artment of Dermatology, Erasmus MC, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands. Tel.: +31
mc.nl (L.M. Hollestein).
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Incidence rates of cutaneous squamous cell carcinoma
(SCC) are rising in many countries.1–5 Despite the high
incidence rates, population based data on SCC incidence,
survival and mortality in many countries are rather
sparse. Recently, population based studies on incidence
were performed in Ireland, Sweden and Denmark and
demonstrated that age-standardised incidence rates are
rapidly increasing with absolute increases of approxi-
mately 2000 new SCC cases annually in population of
4.5–9 million inhabitants.1–3
SCC and other non-melanoma skin cancers (NMSC)
are not reported to cancer registries in many countries
including Australia and the United States (US) and
therefore incidence rates can only be estimated using
other data sources. Results from a national survey in
Australia in 2002 showed that 118,000 new SCC cases
were diagnosed among the 21 million inhabitants.4
According to estimates from medical claims data in
the US, 2.2 million persons of the 298 million inhabit-
ants in 2006 were treated for NMSC of which roughly
20–30% was SCC.5
Observational cancer registry studies are important
because they provide input for a (European) keratinocy-
tic cancer health care policy. Since the Dutch popula-
tion is ageing and SCC is strongly age-dependent, this
skin cancer will become more frequent. The cosmetic
and functional morbidity associated with SCC is high
because it often occurs on the face and is treated with
surgical excision. About 5% of SCCs progresses to sys-
temic disease for which there is no adequate therapy.
Despite the straightforward treatment for early disease,
but due to the very high incidence, SCC is a major pub-
lic health problem and is one of the most costly
cancers.6
The objective of this study was to describe the recent
trends of SCC incidence rates and relative survival and
to estimate SCC mortality rates in the general Dutch
population.2. Patients and methods
Information on newly diagnosed patients with an inva-
sive cutaneous SCC was obtained from the nationwide
Netherlands Cancer Registry (NCR), which covered the
whole country by combining data from all Comprehen-
sive Cancer Centres in the Netherlands since 1989.7 The
NCR is based on all newly diagnosed malignancies in
the Netherlands by the automated pathological archive
(PALGA). Additional sources are the national registry
of hospital discharge diagnosis, haematology depart-
ments and radiotherapy institutions.7 The followingmor-
phology codes combined with topography ‘skin’ were
considered to be invasive cutaneous SCC: 8010, 8050-
8084 (excluding 8077: intraepithelial neoplasia, 8080:Erythroplasia of Queyrat, 8081: Bowen disease, 8082:
lympho-epithelial carcinoma).
Patient’s demographic characteristics such as gender
and date of birth, and tumour characteristics such as date
of diagnosis, subsite (as speciﬁed in the International
Classiﬁcation of Diseases for Oncology (ICD-O-3),8 his-
tology and stage (Tumour Lymph Node Metastasis
[TNM] classiﬁcation)9 are obtained routinely from the
medical records. The quality of the data is high, due to
thorough training of the administrators and computer-
ised consistency checks at regional and national levels.
Completeness on cutaneous malignancies (excluding
basal cell carcinomas) is estimated to be at least
92.9%.10 Follow-up of vital status of all patients was
calculated as the time from diagnosis to death or until
the end of follow up on the 1st of February 2010. The
information on vital status was initially obtained from
municipal registries and from 1995 onwards from the
nationwide population registries network. These regis-
tries provide virtually complete coverage of all Dutch
citizens, including their dates of death. Information on
the Dutch population size in the past and population size
predictions were obtained from Statistics Netherlands
(Centraal Bureau voor Statistiek [CBS]).
All patients with a ﬁrst primary invasive cutaneous
SCC who were diagnosed between 1st January 1989 and
31st December 2008 in the Netherlands were included
(n = 69,408) (i.e. patients with multiple primary SCC
were only counted once). Age was divided in three groups
of equal size (<70, 70–79 andP80 years). The study per-
iodwas divided in four categories: 1989–1993, 1994–1998,
1999–2003, and 2004–2008 to study trends. TNM was
determined postoperatively, in cases where postoperative
stage was unknown clinical TNM stage was used. Stage I
SCC was less than 2 cm in diameter. Stage II SCC was
larger than 2 cm, stage III SCC invaded deep extradermal
structures or with regional lymph node metastasis and
stage IV SCC had distant metastasis.9 Tumour localisa-
tion was categorised in the following anatomical subsites:
lips (C44.0), eyelid (C44.1), ear (C44.2), face (C44.3),
scalp/neck (C44.4), trunk (C44.5), arms (C44.6), legs
(C44.7) and unknown (C44.8, C44.9). For the period
from 1989–1994 only survival data of ﬁve regional cancer
registrieswere available, which have been shown for other
cancer types to be representative for the whole of the
Netherlands.11 In total, 2262 SCC patients (3.4% of all
patients) with missing vital status were excluded from
our survival analyses.
Mortality due to cutaneous SCC is not registered sep-
arately on death certiﬁcates in the Netherlands, but
deaths due to NMSC (C44 of the ICD-10) are registered
on death certiﬁcates. A recent study using the same data
demonstrated that 91% of all NMSC associated mortal-
ity in the Netherlands is due to SCC.12 SCC mortality
rates were estimated by imputing information on NMSC
deaths from Statistics Netherlands.
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Annual age-standardised incidence and mortality
rates (European Standardised Rates [ESR]) were calcu-
lated by using mid-year population obtained from
Statistics Netherlands. The European standard popula-
tion does not reﬂect the elderly very well and therefore
crude incidence rates were calculated as well. Trends
were analysed by calculating the Estimated Annual Per-
centage Change (EAPC) and by performing joinpoint
regression analyses to identify the year in which a signif-
icant change in incidence rates occurred. Incidence rates
were also calculated per sex, age group, body site and
stage. One patient with unknown sex was excluded from
all analyses which were stratiﬁed by sex.
To predict SCC incidence rates up to 2020 two mod-
els were ﬁtted for predictions with a positive slope.13,14
The ﬁtted models were:
Ecit ¼ nitðai þ bitÞ ð1Þ
Ecit ¼ nitaið1þ btÞ ð2Þ
where Ecit is the expected number of cases in age group i
in the year t, nit is the number of personyears in the same
stratum and ai and b are the model parameters. The ﬁrst
model assumes linear changes over time. The second
model assumes proportional eﬀects for diﬀerent age
groups and therefore within the period of prediction this
model retains the age-dependent pattern of incidence
rates existing in the data. Age-speciﬁc predictions can
therefore be made with a greater accuracy. The second
model was the best ﬁtting model and was used for our
predictions.
Five-year relative survival was calculated by tradi-
tional cohort-based analysis. Due to the very small
numbers of patients diagnosed with stage IV SCC (max-
imal seven patients per year), stage III and IV patients
were combined into one subgroup for survival analyses.
To study the possible changes in survival over time,
multivariate relative survival analyses, using Poisson
regression modelling, were carried out to estimate rela-
tive excess risk (RER) of dying adjusted for follow-up
interval.15 The model was ﬁtted on the ﬁrst 5 years of
follow up after diagnosis. The proportional hazards
assumption was tested with log minus log plots. Hazards
for body site were not proportional, and numbers were
too small for stratiﬁcation, therefore body site was not
included in the model. Exclusion of body site from the
multivariate model had only a small eﬀect on the RER
estimates and did not change the results substantially.
We ran separate models for males and females, because
sex was an independent prognostic factor (p < 0.01) in a
multivariate analysis and we felt it important to present
sex-speciﬁc estimates.
The number of avoidable deaths represented the diﬀer-
ence between the observed number of excess deaths and
the expected number of excess deaths and was calculatedby using the following formula: (1-relative survivalstageIII/
IV)  NstageIII/IV – (1-relative survivalstageI)  NstageIII/IV
where N represents the number of diagnosed patients.
Statistical analyses were performed with SPSS 17.0
statistical software (SPSS Inc., Chicago, IL, USA),
SAS 9.2 statistical software (SAS Institute Inc., Cary,
NC, USA) and Joinpoint version 3.4.3 (National Cancer
Institute, http://surveillance.cancer.gov/joinpoint). All
statistical tests were two-sided and considered signiﬁcant
at the p < 0.05 level.
3. Results
3.1. Incidence
In total, 69,408 patients were diagnosed with primary
invasive SCC during the 20-year study period. The Dutch
population size increased from 14.8 million in 1989 to
16.4 million inhabitants in 2008. The absolute annual
number of SCC patients increased from 2247 in 1989 to
6158 in 2008. In males, the crude incidence rate doubled
between 1989 and 2008 from 20.0 to 42.5 per 100,000
inhabitants. The age-standardised incidence rate (ESR)
increased from 22.2 per 100,000 inhabitants in 1989 to
35.4 per 100,000 inhabitants in 2008. Crude incidence
rates for females increased from 10.4 in 1989 to 32.5
per 100,000 inhabitants in 2008. The age-standardised
incidence rates increased from 7.8 to 20.5 per 100,000
inhabitants. In Table 1, age-standardised incidence rates
of SCC are provided by sex, period of diagnosis, age
group, body site and TNM stage. Incidence rates were
increasing for almost all subgroups. The face was the
most aﬀected body site for both sexes and SCCs on the
ear, neck or scalp were much more frequent in males than
females (Fig. 1). Of all SCCs, 73% was diagnosed in stage
I. The incidence rates of SCC of the skin increased expo-
nentially with age starting at the age of 50 (Table 1,
Fig. 2). The age-speciﬁc incidence rates increased with
each study period with the largest increment during the
most recent period (Fig. 2). Incidence rates that were pre-
viously observed among the 85+ population were already
observed in an almost 10 year younger population
between 2004 and 2008. Joinpoint analyses showed an
accelerated increase in incidence rates since 2002 with
an EAPC of 9.2% (95% conﬁdence interval: 7.5–11.0)
for females and an EAPC of 6.9% (95% CI: 5.8–8.7) for
males since 2003 (Fig. 3). Predictions showed expected
increases of up to 11,827 newly diagnosed SCC patients
per year in 2020 compared to 6158 in 2008 (Table 2), cor-
responding with predicted age-standardised incidence
rates (ESR) of 49.7 per 100,000 inhabitants for males
and 29.8 per 100,000 inhabitants for females.
3.2. Survival
The 5-year relative survival over the entire study
period was 92.0% (95% CI: 91.3–92.8) for males and
Table 1
Numbers, age-standardised incidence rates (ESR) and 5-year relative survival of cutaneous squamous cell carcinoma (SCC) in the Netherlands.
Males Females
ESRa 5-Year relative
survivalb
ESRa 5-Year relative
survivalb
N 1989–
1993
1994–
1998
1999–
2003
2004–
2008
Relative
survival
95% CI N 1989–
1993
1994–
1998
1999–
2003
2004–
2008
Relative
survival
95% CI
Overall 41,556 22.2 24.4 25.3 32.4 92 (91–93) 27,851 8.1 10.0 11.8 17.2 95 (94–96)
Age (years)
<70 14,160 9.1 9.6 9.4 11.5 92 (92–93) 8206 3.6 4.6 5.5 8.1 95 (95–96)
70–79 15,220 149 171 175 226 90 (88–91) 7987 47 58 67 100 94 (93–95)
P80 12,176 314 347 390 520 95 (93–98) 11658 119 141 167 231 95 (93–98)
Body site
Lips 1641 1.4 1.1 0.9 0.9 95 (92–98) 817 0.3 0.4 0.4 0.5 99 (94–103)
Eyelid 552 0.4 0.3 0.4 0.3 94 (88–100) 461 0.2 0.2 0.2 0.3 102 (96–107)
Ear 8257 5.1 5.3 5.0 5.6 93 (91–95) 553 0.2 0.2 0.2 0.3 93 (86–99)
Face 15,125 7.8 8.8 9.4 11.9 93 (92–94) 13463 4.0 4.8 5.3 7.3 95 (94–97)
Scalp/neck 6271 2.7 3.4 3.8 5.6 89 (87–91) 1317 0.4 0.5 0.5 0.8 90 (85–94)
Trunk 2107 0.7 1.0 1.3 2.0 90 (87–92) 2184 0.5 0.8 1.1 1.9 90 (88–93)
Arms 5692 3.2 3.6 3.2 4.3 91 (89–93) 5107 1.5 1.8 2.2 3.4 95 (94–97)
Legs 1423 0.6 0.7 0.9 1.3 95 (92–99) 3628 0.8 1.3 1.8 2.6 95 (93–97)
Unknown 488 0.2 0.2 0.3 0.5 92 (86–99) 321 0.1 0.1 0.1 0.2 95 (88–103)
Stage
I 30,161 14.8 16.4 17.9 25.7 95 (94–95) 20,682 5.3 6.8 8.7 14.2 98 (97–99)
II 3447 1.9 2.0 2.2 2.7 76 (73–79) 2014 0.6 0.6 0.8 1.0 76 (72–80)
III 595 0.4 0.4 0.4 0.4 62 (56–68)c 296 0.1 0.1 0.1 0.1 46 (38–53)c
IV 47 0.0 0.0 0.0 0.0 62 (56–68)c 35 0.0 0.0 0.0 0.0 46 (38–53)c
Unknown 7306 5.0 5.5 4.7 3.7 91 (89–93) 4824 2.0 2.3 2.1 1.9 93 (91–95)
Abbreviations: CI, conﬁdence interval; ESR, European Standardised Rate; N, number of cases.
a ESR per 100,000 person years.
b Relative survival in %.
c Stage III and IV were combined in the survival analyses due to small subgroups.
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year relative survival by sex, age group, body site and
stage is shown in Table 1. No changes over time were
observed (data not shown). Females diagnosed with a
stage III or IV SCC had a signiﬁcantly worse prognosis
compared to males (relative survival of 46% versus 62%,
p < 0.001). This combined stage III/IV group consisted
of 7.2% and 11.1% stage IV SCC in males and females,
respectively.
The relative survival of males with a SCC on the scalp
or neck (88.9%, 95% CI: 86.7–91.0) was signiﬁcantly
lower than that of SCC on lip and ear (95.2%,
95% CI: 92.1–98.2 and 92.9%, 95% CI: 91.1–94.7,
respectively).
To study possible changes in relative survival over
time, multivariate regression analyses on relative survival
were carried out (Table 3). Strikingly, the adjusted RER
of dying among female SCC patients diagnosed with a
stage III or IV SCC was 30.4 times increased compared
to those in stage I. For males with stage III/IV SCC, this
risk was 9.9-fold higher.
To translate this result to absolute diﬀerences, the
number of ‘avoidable deaths’ over a period of 5 years
after diagnosis was calculated. If these patients would
have been diagnosed earlier with a stage I SCC, 143deaths could have been avoided (84 avoidable deaths
per 100 SCC deaths) of the 315 female patients who
were diagnosed with a stage III/IV SCC during the
study period. In the same situation, 203 deaths of the
621 males that were diagnosed with a stage III/IV
SCC could have been avoided resulting in 86 avoidable
deaths per 100 SCC deaths.
3.3. Mortality
During the 20-year study period, 1513 patients died
due to NMSC. The crude mortality rate of NMSC
remained 0.5 per 100,000 person-years between 1989
and 2008, whereas age-standardised mortality rates
decreased slightly from 0.5 per 100,000 person-years in
1989 to 0.4 per 100,000 person-years in 2008, with an
EAPC of –1.9% (95% CI:–3.1 to –0.7).
4. Discussion
To our knowledge, this is the ﬁrst study which
describes detailed trends of incidence rates, relative sur-
vival and mortality rates for cutaneous SCC in the Neth-
erlands. As more population based information on
keratinocytic malignancies in Europe is needed,16,17 this
Fig. 1. Three-year moving averages of age standardised incidence rates of cutaneous squamous cell carcinoma (SCC) in the Netherlands by body
site for males (A) and females (B).
Fig. 2. Age-speciﬁc incidence rates of cutaneous squamous cell carcinoma (SCC) in the Netherlands by period of diagnosis for males (A) and
females (B).
Fig. 3. Joinpoint analyses of age standardised incidence rates (European Standardised Rates) of cutaneous squamous cell carcinoma (SCC) in the
Netherlands, 1989–2008 of males (A) and females (B) with Estimated Annual Percentage Change (EAPC).
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Table 2
Predictions of age-standardised incidence rates and number of newly diagnosed squamous cell carcinoma (SCC) patients up to 2020.
2008 2010 2015 2020
Observed Predicted 95% PI Predicted 95% PI Predicted 95% PI
Males
N 3453 3776 (3610–3942) 5177 (4916–5438) 6925 (6530–7320)
ESR 35.4 36.8 (35.2–38.4) 43.3 (41.1–45.5) 49.7 (46.9–52.2)
Females
N 2705 2797 (2680–2913) 3761 (3620–3901) 4902 (4735–5069)
ESR 20.5 20.5 (19.6–21.4) 25.1 (24.1–26.1) 29.8 (28.7–30.9)
Abbreviations: ESR, European Standardised Rate; N, number of cases; PI, Prediction Interval.
L.M. Hollestein et al. / European Journal of Cancer 48 (2012) 2046–2053 2051study adds important information for the development
of public health policies.
4.1. Incidence
Similar to observations from other countries,2–5 age-
standardised incidence rates increased rapidly: 1.5-fold
for men and threefold for women between 1989 and
2008. Trends in crude rates were even stronger, but
should be interpreted with caution as they are heavily
inﬂuenced by ageing of the population. Relative increases
in incidence were higher among females, because
incidence rates at the beginning of the study were lower
compared to males. The increase in absolute number of
newly diagnosed patients was approximately equal for
both sexes. This may be associated with an equal increase
in the distribution of risk factors for both sexes.
As age-speciﬁc incidence rates also increased, ageing
of the population only partly explains the observed
increases. Most likely, increased number of people are
reaching high levels of cumulative UV exposure, result-
ing in higher SCC risks. This is in line with the observa-
tion that incidence rates of other UV-related skinTable 3
Multivariate analyses on relative survival of cutaneous squamous cell carc
Males
N Univariatea Multivariatea
RER 95% CI RER 95% CI
Period
1989–1993 6353 1.00 1.00
1994–1998 8689 1.35 (0.96–1.91) 1.30 (1.04–1.6
1999–2003 10,199 1.45 (1.05–2.02) b 1.34 (1.07–1.6
2004–2008 14,897 1.08 (0.76–1.53) 1.14 (0.91–1.4
Age (years)
<70 13,642 1.00 1.00
70–79 14,685 1.30 (1.12–1.50)b 1.22 (1.06–1.4
P80 11,811 0.41 (0.20–0.82)b 0.91 (0.71–1.1
Stage
I 29,303 1.0 1.0
II 3341 6.5 (5.1–8.3)b 4.3 (3.6–5.1)
III + IV 621 14.1 (10.7–18.5)b 9.9 (8.1–12.1
Unknown 6873 2.3 (1.7–3.0)b 1.5 (1.2–1.9)
Abbreviations: CI, conﬁdence interval; N, number of cases; RER, relative
a All models are ﬁtted on the ﬁrst 5 years after diagnosis and adjusted fo
b Signiﬁcant.tumours increased more steeply than those of other skin
malignancies in the Netherlands.12,18 Holidays to sunny
countries have become more aﬀordable and popular and
an increasing proportion of the retired Dutch popula-
tion emigrates (temporarily during the winter) to sunny
climates such as Spain, Portugal and South of France,
increasing their cumulative UV exposure considerably.
Also, people may spend more time outdoors during lei-
sure activities (e.g. sports, gardening, walking and bik-
ing) compared to prior generations.
Public health campaigns (against melanoma) have pri-
marily advocated avoidance of sunburns (especially in
children) and to a lesser extent reducing cumulative UV
exposure to the general population. Informing middle-
aged and elderly people about the risk of (cumulative)
UV exposure may be beneﬁcial in reducing the burden of
SCC. However, only informing people about the risk is
not enough to change behaviour and more eﬀective
methods should be explored by health promotion
researchers.
Steep increments in incidence rates were observed
since 2002 for females and 2003 for males, for which there
is no simple explanation. The public campaigns warninginoma (SCC).
Females
N Univariatea Multivariatea
RER 95% CI RER 95% CI
3521 1.00 1.00
3) b 5439 1.11 (0.69–1.78) 0.99 (0.73–1.32)
7) b 7049 0.91 (0.56–1.48) 0.95 (0.72–1.26)
3) 10,998 0.71 (0.41–1.18) 0.83 (0.62–1.11)
7980 1.00 1.00
1)b 7735 1.26 (0.99–1.61) 1.44 (1.16–1.78)b
7) 11,292 1.06 (0.70–1.59) 1.32 (1.02–1.69)b
20,204 1.0 1.0
b 1946 15.3 (8.9–26.2)b 7.7 (5.9–10.0)b
)b 315 55.1 (32.1–94.7)b 30.4 (23.2–39.7)b
b 4542 3.9 (2.2–7.1)b 1.9 (1.4–2.6)b
excess risk.
r follow-up time of the patients.
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this increase, but a recent study showed that increased
skin cancer surveillance resulted in a higher likelihood
of being diagnosed with truncal BCC and not SCC sug-
gesting that this bias has relatively little impact on our
ﬁndings.19 Another possibility is an improvement in com-
pleteness of the national cancer registration since 2002.
However, in 1990 the completeness of skin malignancies
(excluding basal cell carcinomas) was already 92.9%10
and a small increase in completeness could not explain
the observed increases in SCC. The increased number
of solid organ transplantations and the associated immu-
nosuppressive drug use may have contributed to the
increased incidence rates as well.20 The number of solid
organ transplantations increased from 511 in 1989 to
1048 in 2008 and the total number of immunosuppressive
drug users increased fourfold from 25,400 in 1994 to
101,600 users in 2008 (personal communication).21,22
Unfortunately, in our database we are not able to identify
SCC patients who had a solid organ transplantation or
who were long term immunosuppressive drug users for
other reasons. The increased use of biologics in immune
mediated inﬂammatory diseases may also contribute to
the increased SCC incidence in the last decade.23,24 How-
ever, these iatrogenic risk factors would result in a more
gradual increase in incidence rates and not the abrupt
accelerations in incidence rates since 2002.
Incidence rates increased among almost all body
sites, except for males with SCC on the lips. This pattern
followed the decreasing trend of smoking among males
and the increasing trend of smoking among females in
the Netherlands, which is an important risk factor for
developing lip cancer.25,26 An Israeli study found a com-
parable pattern and observed a 40-fold higher incidence
of cancer of the external lip compared to cancer of the
internal lip, suggesting that the role of sun exposure is
more important than smoking in causing SCC.27
We may have underestimated the SCC incidence
rates, because we may have missed some cases due to
the following reasons16: the number of non-hospital
practices that treat SCC has increased in the last decade
and not all of these private practices are aﬃliated to the
national cancer registry. Furthermore, not all SCCs are
diagnosed, especially in elderly people with multiple
comorbidities where skin cancers are often not treated.
Also a small proportion of SCC may be treated without
histological conﬁrmation and will therefore not be regis-
tered in the cancer statistics.284.2. Survival and mortality
Only a small proportion of all SCC patients were at
high risk of dying at time of diagnosis (1.4% diagnosed
in stage III/IV), but some lesions may progress after diag-
nosis also leading to death. It is estimated that in Europe,annually 2016 deaths are due to SCC.29 In the Nether-
lands we observed a small decreasing trend in NMSC
mortality, mainly caused by SCC, which is in line with
studies from Finland and the United States.30,31
The observed 5-year relative survival rates were com-
parable with those observed in Denmark32 and no sig-
niﬁcant changes over time were observed. Relative
survival was better for females than for males, in con-
trast to relative survival of advanced disease: a third of
all male patients and almost half of all female patients
with advanced disease died. SCCs in the head and neck
region were associated with a signiﬁcantly lower relative
survival. Truncal SCCs in men and women also had a
negative impact on survival which may be explained
by a diagnostic delay (i.e. truncal SCCs may have been
missed more easily by patients and physicians).
Due to a higher prevalence of mortality risk factors
(e.g. solid organ transplantation, use of immunosuppres-
sive drugs) among SCC patients compared to the general
population, we might have overestimated SCC-speciﬁc
mortality, resulting in lower relative survival estimates.
Increased tumour thickness, increased horizontal
size, immunosuppression and localisation on the ear
and possibly the lips are known to be prognostic factors
for the development of metastasis, but were not all avail-
able in the cancer registry.33 The Dutch SCC guideline,
approved in 2010, recommends recording the tumour
thickness in the pathology report, which is of interest
for future evaluations.344.3. Conclusion
Incidence rates of SCC increased rapidly. Overall
relative survival was stable and the mortality rate due
to NMSC decreased slightly during the study period.
We recommend that primary prevention programmes
aim to reduce the cumulative amount of UV exposure
among the young and the older population. Secondary
prevention programmes should encourage the elderly to
recognise skin changes and to seek early diagnosis to pre-
vent progression of the lesion.Conﬂict of interest statement
None declared.
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